Our study validated the SLC19A1 c.80 variant as being associated with delayed methotrexate clearance and the TYMS 6bp deletion variant as a risk of developing gastrointestinal toxicity in pediatric ALL patients. The gene discussed is TYMS; the disease is acute lymphoblastic leukemia.